Regulatory approvals from FDA and EUA and growing investment and policy support from governments worldwide forecast a bright outlook for the biotech industry in the long run.

With the Allergan acquisition, Actavis will be able to strengthen its global presence especially in Canada, Europe and Southeast Asia and other high-value growth markets like China, India, the Middle East and Latin America.

It has been an eventful year in the big pharma and biotech space, and a lot is happening in this space that biotech investors should take note of.

Allergan’s presence across different segments will help maintain growth.

U.S. stocks turned lower in afternoon trading on Wednesday, with major indexes erasing earlier gains as a shooting at the Canadian parliament unnerved investors and Boeing and Biogen sold off following results.

December E-mini S&Ps (ESZ14 -0.21%) this morning fell back from a 1-week high in overnight trade and are down -0.15% and European stocks slipped-0.09%.